and other data for a number of reasons, such as keeping FT Sites reliable and secure,
personalising content and ads, providing social media features and to
analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Addressing this IP issue is crucial to ensuring pharmaceutical products are available in future emergencies
Pharmaceutical companies should temporarily surrender IP and expertise for the good of humanity